Alentis announces first patient in lixudebart Phase 2 trial
Alentis is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They announced today the first patient dosed in a Phase 2 clinical trial of lixudebart for the treatment of organ fibrosis.
Double builds companies. Occasionally on our own, more usually with others. Sometimes part of the founding team, sometimes working with established companies to help get things moving.
FIND US AT
The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH, United Kingdom
